Models,Multiomics

Dataset Information

0

Zhao2020 - SUQC model of COVID-19 transmission dynamics in Wuhan, Hubei, and China


ABSTRACT: Background - The coronavirus disease 2019 (COVID-19) is rapidly spreading in China and more than 30 countries over last two months. COVID-19 has multiple characteristics distinct from other infectious diseases, including high infectivity during incubation, time delay between real dynamics and daily observed number of confirmed cases, and the intervention effects of implemented quarantine and control measures. Methods - We develop a Susceptible, Un-quanrantined infected, Quarantined infected, Confirmed infected (SUQC) model to characterize the dynamics of COVID-19 and explicitly parameterize the intervention effects of control measures, which is more suitable for analysis than other existing epidemic models. Results - The SUQC model is applied to the daily released data of the confirmed infections to analyze the outbreak of COVID-19 in Wuhan, Hubei (excluding Wuhan), China (excluding Hubei) and four first-tier cities of China. We found that, before January 30, 2020, all these regions except Beijing had a reproductive number R > 1, and after January 30, all regions had a reproductive number R lesser than 1, indicating that the quarantine and control measures are effective in preventing the spread of COVID-19. The confirmation rate of Wuhan estimated by our model is 0.0643, substantially lower than that of Hubei excluding Wuhan (0.1914), and that of China excluding Hubei (0.2189), but it jumps to 0.3229 after February 12 when clinical evidence was adopted in new diagnosis guidelines. The number of unquarantined infected cases in Wuhan on February 12, 2020 is estimated to be 3,509 and declines to 334 on February 21, 2020. After fitting the model with data as of February 21, 2020, we predict that the end time of COVID-19 in Wuhan and Hubei is around late March, around mid March for China excluding Hubei, and before early March 2020 for the four tier-one cities. A total of 80,511 individuals are estimated to be infected in China, among which 49,510 are from Wuhan, 17,679 from Hubei (excluding Wuhan), and the rest 13,322 from other regions of China (excluding Hubei). Note that the estimates are from a deterministic ODE model and should be interpreted with some uncertainty. Conclusions - We suggest that rigorous quarantine and control measures should be kept before early March in Beijing, Shanghai, Guangzhou and Shenzhen, and before late March in Hubei. The model can also be useful to predict the trend of epidemic and provide quantitative guide for other countries at high risk of outbreak, such as South Korea, Japan, Italy and Iran.

DISEASE(S): Covid-19

SUBMITTER: Kausthubh Ramachandran  

PROVIDER: BIOMD0000000962 | BioModels | 2024-09-02

REPOSITORIES: BioModels

Dataset's files

Source:
Action DRS
BIOMD0000000962?filename=Zhao2020.cps Other
BIOMD0000000962?filename=Zhao2020.omex Other
BIOMD0000000962?filename=Zhao2020.sedml Other
BIOMD0000000962?filename=Zhao2020.xml Xml
Items per page:
1 - 4 of 4
altmetric image

Publications

Modeling the epidemic dynamics and control of COVID-19 outbreak in China.

Zhao Shilei S   Chen Hua H  

Quantitative biology (Beijing, China) 20200311 1


<h4>Background</h4>The coronavirus disease 2019 (COVID-19) is rapidly spreading in China and more than 30 countries over last two months. COVID-19 has multiple characteristics distinct from other infectious diseases, including high infectivity during incubation, time delay between real dynamics and daily observed number of confirmed cases, and the intervention effects of implemented quarantine and control measures.<h4>Methods</h4>We develop a Susceptible, Un-quanrantined infected, Quarantined in  ...[more]

Similar Datasets

2024-09-02 | BIOMD0000000957 | BioModels
2024-09-02 | BIOMD0000000981 | BioModels
2024-09-02 | BIOMD0000000970 | BioModels
2024-09-02 | BIOMD0000000971 | BioModels
2021-11-03 | PXD024547 | Pride
2024-09-02 | BIOMD0000000958 | BioModels
2024-09-02 | BIOMD0000000991 | BioModels
| 2718801 | ecrin-mdr-crc
| PRJNA776394 | ENA
2024-01-26 | PXD041904 | Pride